baber/WOPTO huggingface dataset:
Patent JP-H0818817-B2 (JP)
IPC: C01B39/14
Filed: 1986-07-24
Abstract: The present invention provides synthetic, finely divided water-insoluble layered silicates having a smectite-like crystal phase, with increased contents of bound alkali and silicate and a distinctly reduced swelling power in aqueous suspension relative to pure layered silicates of this type. The synthetic layered silicate of this invention has the following oxide summation formula MgO.aM2O.bAl2O3.cSiO2.nH2O wherein M is selected from the group consisting of sodium and a mixture of sodium and lithium said mixture having a molar ratio of sodium to lithium of at least about 2, n represents the number of water molecules bound in the crystal phase, and a, b, c and n each represent a number having a value within the following ranges: a is from about 0.05 to about 0.4 b is from 0 to about 0.3 c is from about 1.2 to about 2.0, and n is from about 0.3 to about 3.0.
Patent JP-H0478611-B2 (JP)
IPC: A61K9/22
Filed: 1981-12-01
Abstract: A pharmaceutical oral controlled release multiple-units formulation in which individual units comprise cross-sectionally substantially homogeneous cores containing particles of a sparingly soluble active substance, the cores being coated with a coating which is substantially resistant to gastric conditions, but which is erodable under the conditions prevailing in the small intestine, in particular an enteric coating which is substantially insoluble at a pH below 7 such as Eudragit<sup>0</sup> S (an anionic polymerisate of methacrylic acid and methacrylic acid methyl ester), is prepared by a process comprising comminuting an active substance together with a substance which is readily soluble in intestinal fluids such as an anionic detergent to obtain particles containing the active substance in intimate admixture with the readily soluble substance, combining the resulting particles into cross-sectionally substantially homogeneous cores together with components which accelerate the disintegration of the cores in intestinal fluids such as talc and sucrose, coating the individual cores with the coating, and combining a multiplicity of the coated cores into a capsule or tablet formulation.As the coating is erodable in an alkaline environment only, the active substance is not released until the units arrive at a section ofthe small intestine with an alkaline pH. Thus, a reduction and delay of the peak plasma concentration is obtained without affecting the extent of drug availability.A coating of the above-defined type may also be used when the active substance is a substance which exerts an irritating effect on the gastric mucosa and/or is unstable in an acidic environment.
Patent JP-2642637-B2 (JP)
IPC: G03F1/00
Filed: 1987-08-18
Granted: 1997-08-20
Abstract: A dust-proof film comprising a mask and a pellicle film spaced apart therefrom by a pellicle frame such as to prevent a foreign substance from contacting the mask wherein a paint layer is provided on the inner surface of the pellicle frame between the mask and the pellicle film, or wherein the pellicle frame is attached to the mask by a tape comprising a foamed substrate and an adhesive layer provided on each surface thereof, the inner surface of the foamed substrate having a paint layer provided thereon, or wherein the pellicle frame is attached to the mask by a tape comprising an unfoamed substrate and an adhesive layer provided on each surface thereof, or wherein the pellicle film is attached to the mask by a tackifier, such as to prevent a foreign substance from contacting the mask.
Patent JP-3059789-B2 (JP)
IPC: C08G18/32
Filed: 1991-08-08
Granted: 2000-07-04
Abstract: Binder combinations essentially comprising a polyisocyanate component and a polyisocyanate-reactive component are used as binders in two-component automotive refinish (repair) paints, the reactive component comprising a mixture of i) a specific, ester-containing, disecondary diamine and ii) polyhydroxy acrylates or mixtures of hydroxy acrylates and polyester-polyols.
Patent JP-3272165-B2 (JP)
IPC: F16K3/00
Filed: 1994-09-21
Granted: 2002-04-08
Abstract: A leakproof double seat valve comprises two slide-valve bodies (1, 2) in a valve housing (3) with conduit connections (4, 5). In the closed position, the two slide-valve bodies (1, 2), which can be actuated independently of one another, rest against valve seats (6, 7) in the valve housing (3) and are at a distance apart, thus forming a leakage cavity (8). During the opening process, the first slide-valve body (1) can be brought to rest against the other, second slide-valve body (2) before it leaves its valve seat (6), the former movement involving a reduction in the size of the leakage cavity (8). The second slide-valve body (2) is provided with a tubular extension (9) which is passed out of the valve housing (3) in a sealed manner and connects the leakage cavity (8) to the surroundings of the valve. In a double seat valve of this kind, optimum cleaning with minimum consumption of flushing agent is achieved by virtue of the fact that the two slide-valve bodies (1, 2) can each be moved independently of the other by a partial stroke in the opposite direction to that of opening into a flushing position in which the slide-valve body (1 or 2) is free of its valve seat (6 or 7) and rests against a housing stop (13 or 14) provided with openings (11 or 12) for flushing agent.   <IMAGE>
Patent JP-3820643-B2 (JP)
IPC: B60L50/16
Filed: 1996-08-30
Granted: 2006-09-13
Abstract: PROBLEM TO BE SOLVED: To attain limp home function by providing a torque control means for controlling a driving means with brake pedal operation, detected by a brake sensor, as input so as to change output torque of a drive source. SOLUTION: A driving means 2 controls output torque of a drive source 1. A power transmission 8 connects wheels 91 to the drive source 1 through a differential gear 90. A control device (ECU) 3 controls the driving means 2 and the power transmission 8. An accelerator sensor 4 detects the depressed quantity of an accelerator pedal. A vehicle speed sensor 6 detects vehicle speed from the rotation of an output shaft of the power transmission 8. A shift position sensor 7 detects the position of a shift lever for operating the power transmission 8, from the displacement of a shift link or the like. With brake operation as input, the driving means 2 is thus controlled to change the output torque of the drive source, so that a vehicle can travel to an expected place without hindrance even at the time of the failure of the accelerator sensor 4.
Patent JP-2757982-B2 (JP)
IPC: C12N15/16
Filed: 1996-09-25
Granted: 1998-05-25
Abstract: Biologically active heterodimeric human FSH and other hormones similarly composed of alpha and beta subunits are synthesised in cells transfected with one or more expression vectors comprising heterologous DNA encoding each of the subunits.
Patent JP-2520580-B2 (JP)
IPC: C07C33/14
Filed: 1994-10-04
Granted: 1996-07-31
Abstract: The present invention relates to new intermediates in the preparation of vitamin A and carotenoids corresponding to the following formula (II): <IMAGE> as well as to their process of preparation and to their use.t
Patent JP-3640477-B2 (JP)
IPC: F16H9/00
Filed: 1996-10-11
Granted: 2005-04-20
Abstract: A hydraulic control apparatus for a continuously variable transmission which can produce stable drive pulley pressure and driven pulley pressure and also control the speed change time. The line pressure regulated by the regulator valve 22 is supplied to the control valve 24DR of the drive pulley 5 and to the control valve 24DN of the driven pulley 7. These control valves regulate the line pressure according to the PB pressure and the PC pressure output from the solenoid valves SOL-B, SOL-C, respectively, and produce the drive pulley pressure PDR and the driven pulley pressure PDN. When the PB pressure and the PC pressure are both zero, and PDR = PDN, the control apparatus maintains the same gear ratio. When the PB pressure is increased from zero while keeping the PC pressure at zero, i.e. PDR > PDN, the gear ratio changes toward the high-speed overdrive. When the PC pressure is increased from zero while holding the PB pressure at zero, i.e. PDR < PDN, the gear ratio changes toward the low-speed gear. <IMAGE>
Patent JP-2933931-B2 (JP)
IPC: A61K9/72
Filed: 1987-11-06
Granted: 1999-08-16
Abstract: Disclosed are small particle aerosol liposome and liposome-drug combinations advantageous for the treatment of a wide variety of diseases. Different methods of preparation of liposome and liposome-drug combinations are described which can be used in small particle aerosol treatment.
Patent JP-2929291-B2 (JP)
IPC: H01L29/36
Filed: 1986-12-04
Granted: 1999-08-03
Abstract: A MOS field effect transistor comprises a substrate (1) of a first conductivity type, source and drain regions of a second conductivity type having a lightly doped region and a heavily doped region therein being deposited by an epitaxial growth technique respectively in a source forming region (4) and a drain forming region (3) formed by etching the substrate, a gate insulated film (2) provided on a surface of the substrate (1) and a gate (5) provided on the gate insulated film having a relatively small overlap with each of the source region and drain region.
Patent JP-2542656-B2 (JP)
IPC: H01L29/72
Filed: 1987-12-22
Granted: 1996-10-09
Abstract: A complementary Lateral Insulated Gate Rectifier (LIGR) includes two complementary LIGR structures fabricated in adjacent surface-adjoining semiconductor wells of the same conductivity type in a semiconductor substrate. The two LIGR structures are of generally similar configuration, thus simplifying the manufacturing process, and the proposed design additionally permits the n-channel and p-channel LIGR structures to have comparable "on" resitances. The two LIGR structures, otherwise isolated by a portion of the substrate separating the two semiconductor wells, are connected together by a common source electrode. The resulting complementary Lateral Insulated Gate Rectifier features a compact, integrated structure in which the "on" resistances of both the n-channel and p-channel portions of the device are comparable.
Patent JP-2906970-B2 (JP)
IPC: G10L25/00
Filed: 1993-12-28
Granted: 1999-06-21
Abstract: Analysis data are provided which are indicative of plural components making up an original sound waveform. The analysis data are analyzed to obtain a characteristic concerning a predetermined element, and then data indicative of the obtained characteristic is extracted as a sound or musical parameter. The characteristic corresponding to the extracted musical parameter is removed from the analysis data, and the original sound waveform is represented by a combination of the thus-modified analysis data and the musical parameter. These data are stored in a memory. The user can variably control the musical parameter. A characteristic corresponding to the controlled musical parameter is added to the analysis data. In this manner, a sound waveform is synthesized on the basis of the analysis data to which the controlled characteristic has been added. In such a sound synthesis technique of the analysis type, it is allowed to apply free controls to various sound elements such as a formant and a vibrato.
Patent JP-2745400-B2 (JP)
IPC: C11D3/10
Filed: 1995-12-29
Granted: 1998-04-28
Abstract: "Builder" agent, for a detergent composition, consisting of an aqueous solution of an alkali metal silicate, in particular of sodium or potassium, with an SiO2/M2O molar ratio of the order of 1.6 to 4, and of an inorganic product, inert with respect to the silicate, the said inorganic product representing from 5 to less than 55 % of the total weight expressed on a dry basis and the remaining water in combination with the silicate/silicate expressed on a dry basis ratio by weight being greater than or equal to 33/100, preferably greater than or equal to 36/100. Use of this builder agent in detergent compositions, more particularly in powder detergent compositions, in particular for washing machines and dishwashers.
Patent JP-3863564-B2 (JP)
IPC: G01N33/531
Filed: 1996-05-24
Granted: 2006-12-27
Abstract: The present invention is directed to an in vitro aqueous composition comprising a drug, preferably tacrolimus or rapamycin, having enhanced stability. The invention utilizes a binding protein, preferably antibodies to tacrolimus or rapamycin, to stabilize the drug in an aqueous matrix.
Patent JP-H0246478-B2 (JP)
IPC: B67B7/60
Filed: 1985-03-29
Abstract: In a can opener having a traction wheel (18) for driving the end seam (26) of a can past the opener, and a cutter wheel (16) for severing the outer seaming wall of the seam, the axes (36,38) of the wheels being mutually perpendicular, the working parts are carried in a common cartridge (58) of metal, mounted removably in the housing (10) of the opener, the cutter wheel and its spindle (74) being integral with each other and mounted in a separate bearing cup (66) fixed in the body (60) of the cartridge and having a thrust bearing (68) remote from the cutter wheel. The housing carries a projecting abutment (54) having a forwardly curved seam-engaging surface which enables a variety of shapes and sizes of cans to be opened.
Patent JP-3462497-B2 (JP)
IPC: C12N5/10
Filed: 1992-02-06
Granted: 2003-11-05
Abstract: PCT No. PCT/EP92/00274 Sec. 371 Date Oct. 4, 1993 Sec. 102(e) Date Oct. 4, 1993 PCT Filed Feb. 6, 1992 PCT Pub. No. WO92/13956 PCT Pub. Date Aug. 20, 1992Rice anther-specific promoters which are of particular utility in the production of transgenic male-sterile monocots and plants for restoring their fertility.
Patent JP-4429385-B2 (JP)
IPC: C12N15/63
Filed: 1995-07-06
Granted: 2010-03-10
Abstract: The present invention is directed to mammalian enzymatically active calpain produced in insect cells by recombinant means. Recombinant vectors and baculoviruses containing cDNA encoding the 80 kDa subunit, 30 kDa subunit, and both subunits are described. Methods for producing recombinant enzymatically active mammalian calpain are also described.
Patent JP-3980052-B2 (JP)
IPC: C07D207/09
Filed: 1994-08-09
Granted: 2007-09-19
Abstract: Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R1(m) represents up to 6 substituents, K represents -O-, -S-, -CH2-, -N(R2)- or -N(COR2)-, in which R2 is H or C1 to C3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors.
Patent JP-3036075-B2 (JP)
IPC: D06M101/00
Filed: 1992-03-02
Granted: 2000-04-24
Abstract: The invention relates to highly processable, hydrophobic aramid fibers of high modulus, improved surface frictional properties, scourability, low abrasion depositing, low fibrillation obtainable by surface reaction of an aromatic polyamide fiber with a surface reactant comprising a ketene dimer [R1R2C2O][R1R2C2O](I). The invention further relates to a process for the production and the use of said fibers.
Patent JP-4592830-B2 (JP)
IPC: A61K9/14
Filed: 1994-08-16
Granted: 2010-12-08
Abstract: Aqueous formulations of nerve growth factor suitable for lyophilization and subsequent reconstitution in which nerve growth factor is admixed with sugars and buffer are provided.
Patent JP-3351523-B2 (JP)
IPC: A61K47/34
Filed: 1992-04-11
Granted: 2002-11-25
Abstract: PCT No. PCT/EP92/00825 Sec. 371 Date Oct. 18, 1993 Sec. 102(e) Date Oct. 18, 1993 PCT Filed Apr. 11, 1992 PCT Pub. No. WO92/18108 PCT Pub. Date Oct. 29, 1992The invention relates to the use of free radical-reactive cross-linker components based on olefinically unsaturated esters of lower hydroxycarboxylic acids and/or oligomers thereof for modifying depot materials, and especially retard systems, which contain medicinal and/or biological valuable materials in admixture with a carrier material in a sustained release form. The cross-linkers are present as polymer compounds in the application form of the retard system and may be provided in the retard system or depot material to be applied in a largely homogeneous as well as in a non-uniform distribution. The invention also relates to retard systems which contain medicinal and/or biological valuable materials and have been based on oligomer and/or polymer compounds of lower hydroxycarboxylic acids as carrier materials providing a sustained release of the active substance. The retard systems and/or depot materials are modified with polymer compounds prepared from olefinically unsaturated esters of lower hydroxycarboxylic acids and/or oligomers thereof.
Patent JP-2612641-B2 (JP)
IPC: G01N21/27
Filed: 1990-06-21
Granted: 1997-05-21
Abstract: PCT No. PCT/GB90/00953 Sec. 371 Date Dec. 19, 1990 Sec. 102(e) Date Dec. 19, 1990 PCT Filed Jun. 21, 1990 PCT Pub. No. WO90/15985 PCT Pub. Date Dec. 27, 1990.The invention relates to a method of optical analysis which can advantageously be used in conjunction with optical assay techniques, particularly those wherein evanescent signals are to be analysed. The method makes use of the properties of an optical structure (described herein) which allows easy angular discrimination of optical signals emerging from a test object. The invention also relates to apparatus for use in said methods.
Patent JP-3187419-B2 (JP)
IPC: A61K39/116
Filed: 1991-05-24
Granted: 2001-07-11
Abstract: The invention provides vaccine components and compositions useful for vaccinating pigs against Mycoplasma hyopneumoniae and secondary pathogenic infections.
Patent JP-3415840-B2 (JP)
IPC: C07K16/00
Filed: 1993-11-25
Granted: 2003-06-09
Abstract: A process for efficiently producing a foreign protein, in particular, a novel foreign protein suitable for the expression of a recombinant antibody with eucaryotic cells by the genetic recombination techniques, wherein a cell containing a foreign gene introduced thereinto can be cultured in a serum-free medium by using as a host cell for foreign gene expression a fused cell obtained by the fusion of mouse myeloma with a lymphoid cell and culturable in a serum-free medium.
Patent JP-2771332-B2 (JP)
IPC: C07K14/765
Filed: 1994-12-21
Granted: 1998-07-02
Abstract: PCT No. PCT/EP94/04265 Sec. 371 Date Feb. 29, 1996 Sec. 102(e) Date Feb. 29, 1996 PCT Filed Dec. 21, 1994 PCT Pub. No. WO95/17427 PCT Pub. Date Jun. 29, 1995The invention addresses protein aggregates that are acylated with -CO- R groups, wherein R is a branched or non-branched C1-C4 alkyl residue which can be substituted with hydroxy, carboxy, SO3H or PO3H2 groups. These protein aggregates can be used to increase the intensity of signals and avoid false-positive results in immunoassays for the detection of antibodies. The inventions also adresses a reagent with a buffer and a binding reagent with an immunological binding partner containing said protein aggregate.
Patent JP-3883204-B2 (JP)
IPC: A61K31/565
Filed: 1994-12-20
Granted: 2007-02-21
Abstract: Disclosed is a wet method for preparing solid pharmaceutical composition for oral administration of low-dose medications whose active ingredients have steroidal or steroid-like structures. The meethod suspends medicaments with low solubility in an aqueous binder solution with a trace amount of surfactant. The aqueous suspension is then blended with fillers and granulated. The dried granules can be made into capsules, tablets, lozenges, troches, sustained or delayed release products or suspensions.
Patent JP-3483886-B2 (JP)
IPC: A23L13/40
Filed: 1994-03-18
Granted: 2004-01-06
Abstract: The method for production of an acidified edible gel on milk basis comprises addition of transglutaminase to milk, followed by a heat treatment. Hereby a functionally and/or organoleptically satisfactory edible gel is obtained, which can be used as a yoghurt mousse or cheese.
Patent JP-3462877-B2 (JP)
IPC: H01M4/06
Filed: 1994-01-21
Granted: 2003-11-05
Abstract: The present invention is an improved alkaline cell wherein the capacity of each of the anode and cathode is at least 0.48 and more preferably to at least 0.5 ampere-hour per cm3 of internal cell volume. This is achieved by employing zinc densities of at least 1.4 grams of zinc per cm3 of anode volume and MnO2 densities of at least 2.7 grams of MnO2 per cm3 of cathode volume.
Patent JP-3620857-B2 (JP)
IPC: G06T1/60
Filed: 1997-02-25
Granted: 2005-02-16
Abstract: A main CPU 11, a main memory 12, a main DMAC (direct memory access controller) 13 and a picture processing unit (graphic processing unit or GPU) 15 are interconnected over a main bus 1. In an input/output unit of each of the main CPU 11 and the GPU 15 are mounted programmable packet engines (PPE) 112, 152 capable of modifying the data packetizing/unpacketizing sequence in order to perform packet transfer with freedom in the packet form. This affords freedom to the packet form to realize efficient development and packing of packet data and efficient drawing processing. <IMAGE>
Patent JP-4233610-B2 (JP)
IPC: A61K31/429
Filed: 1998-01-28
Granted: 2009-03-04
Abstract: The carbapenem derivatives represented by the following formula (I) is disclosed. These compounds have strong anti-bacterial activities against bacteria including methicillin resistant Staphylococcus aureus, penicillin resistant Streptococcus pneumoniae, Enterococci, influenza, and  beta -lactamase producing bacteria, and have high stabilities to DHP-1. <CHEM> wherein R<1> represents hydrogen or methyl, either one of R<2>, R<3>, R<4>, or R<5> represents the bond to the 2-position on the carbapenem ring, and the remaining three respectively represent hydrogen, halogen, nitro, cyano, alkyl, cycloalkyl, alkylthio, alkenyl, formyl, alkylcarbonyl, alkoxycarbonyl, aminosulfonyl, aryl carbonyl, aryl , carbamoyl, N-lower alkylcarbamoyl, N,N-di-lower alkylaminocarbonyl, lower alkoxyiminomethyl, or hydroxyiminomethyl, R<6> is not present or represents alkyl, cycloalkyl, or alkenyl, and R is not present, or represents hydrogen or a group which may be metabolically hydrolyzed in the body, provided that when R<6> is not present, R represents hydrogen or a group which may be metabolically hydrolyzed in the body, and when R<6> is present, R is not present, and the compound forms an inner salt.
Patent JP-3764174-B2 (JP)
IPC: A61K38/00
Filed: 1998-03-20
Granted: 2006-04-05
Abstract: Zinc free insulin crystals having a diameter below 10 µm suitable for pulmonary administration are disclosed. The crystals have a reduced tendency to associate into aggregates in the dry powder.
Patent PL-160015-B2 (PL)
Title: Method for obtaining tert-buthylhydroxyamine and its hydroxylated derivatives
IPC: C07C239/10
Filed: 1989-12-15
Abstract: 1. A method of producing tert-butyl hydroxylamine and its derivatives, with the generalized formula R<1>R<2> (CH3)C-NH-OH, where R<1> and R<2> stand for methyl or hydroxymethyl group and may or may not be identical, characterised in that amine with the generalized formula R<1>R<2> (CH3)C-NH2, in which the symbols have the above meanings, is subjected to electrochemical oxidation in a basic medium, and further anolyte containing a nitro compound with the generalized formula R<1>R<2> (CH3)-C-NO2, in which the symbols have the above meanings, is acidified to pH 2-3 and is subjected directly to electrolytic reduction.